the clinical study of Ulinastatin for Injection in the pancreatic fistula and prognosis of pancreatic cancer with operation

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15006940

Enrollment

Unknown

Registered

2015-08-20

Start date

2016-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

A:using Ulinastatin for Injection in the 5 days of postopreation

B:using Ulinastatin for Injection in the 3 days of postopreation

C:normal saline

Eligibility

Sex/Gender

All

Age

20 Years to 75 Years

Inclusion criteria

Inclusion criteria: Clinical diagnosed with pancreatic cancer, no matter gender, <70 years old, planning to have pancreaticoduodenectomy , or body and tail pancreatectomy. and patients have no other diseases, like diabetes, hypertension, congenital heart disease, COPD and so on.

Exclusion criteria

Exclusion criteria: 1. once had serious or unstable diseases of cardiovascular system, respiratory system,hematological system, liver or kidney; 2.pregnancy, lactating mother, children and elderly; 3.allergic to Ulinastatin for Injection; 4. patients with recuurent tumors or once had other digestive system neoplasm or had chemoradiotherapy before operation; 5.the tumor can not be resected during operation or have palliative operation owing to the metastasis in peritoneal; 6. have distant metastasis or others malignant cancer with relevant inspection before operation.

Design outcomes

Primary

Measure	Time frame
amylase;IL-2;IL-6;IL-8;hospital stay;postoperative complications;	—

Countries

China

Contacts

Public ContactChen Huang

richard-hc@hotmail.com+86 13381758371

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026